Ganesha (psychedelic)

Revision as of 19:47, 27 September 2011 by WikiBot (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Chemical name 3,4-methyl-2,5-dimethoxy-amphetamine or
Chemical formula C13H22NO2
Chemical structure of Ganesha
Chemical structure of Ganesha

Ganesha, or 2,5-dimethoxy-3,4-dimethylamphetamine, is a lesser-known psychedelic drug. It is also a substituted amphetamine. It was first synthesized by Alexander Shulgin. In his book PIHKAL (Phenethylamines I Have Known and Loved), the dosage range is listed as 24-32 mg. Ganesha is sold in the form of dark red crystals. The drug is usually taken orally, although other routes such as rectally may also be used. Ganesha is synthesized from 2,5-dimethoxy-3,4-dimethylbenzaldehyde. Ganesha is the amphetamine analogue of 2C-G. It is a particularly long lasting drug, with the duration listed in PIHKAL as being 18 - 24 hours, which might make it undesirable to some users. It is named after the Hindu deity, Ganesha. Very little data is known about the dangers or toxicity of Ganesha. Effects of Ganesha include:

  • Strong closed-eye visuals
  • An increased appreciaciation of music
  • Powerful relaxation and tranquility



Dosage: 12-18 mgs

Duration: 8-12 hours

Effects: Enhancement of reading, no visuals or body load.

2C analog: 2C-G-3


Dosage: unknown

Duration: unknown

Effects: unknown

2C analog: 2C-G-4


Dosage: 14-20 mgs

Duration: 16-30 hours

2C analog: 2C-G-5

See also

External links


Navigation WikiDoc | WikiPatient | Up To Date Pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies